Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
F 7.87 -6.46% -0.54
FDMT closed down 3.0 percent on Wednesday, November 20, 2024, on 82 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
20 DMA Support Bullish -6.46%
Upper Bollinger Band Touch Strength -6.46%
20 DMA Support Bullish -9.26%
20 DMA Support Bullish -5.45%
Upper Bollinger Band Touch Strength -5.45%
Slingshot Bearish Bearish Swing Setup -10.91%
Crossed Above 20 DMA Bullish -10.91%
Pocket Pivot Bullish Swing Setup -10.91%
Wide Range Bar Range Expansion -10.91%
Lower Bollinger Band Walk Weakness -10.91%

   Recent Intraday Alerts

Alert Time
1.5x Volume Pace about 3 hours ago
Down 5% about 3 hours ago
Down 3% about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 2 % about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Products Choroideremia Gene Therapy Of The Human Retina

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 36.25
52 Week Low 7.32
Average Volume 959,103
200-Day Moving Average 20.12
50-Day Moving Average 9.88
20-Day Moving Average 8.24
10-Day Moving Average 8.23
Average True Range 0.60
RSI (14) 45.65
ADX 32.14
+DI 18.03
-DI 18.30
Chandelier Exit (Long, 3 ATRs) 7.39
Chandelier Exit (Short, 3 ATRs) 9.11
Upper Bollinger Bands 8.75
Lower Bollinger Band 7.72
Percent B (%b) 0.67
BandWidth 12.44
MACD Line -0.36
MACD Signal Line -0.56
MACD Histogram 0.1941
Fundamentals Value
Market Cap 414.95 Million
Num Shares 49.3 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -3.17
Price-to-Sales 62.23
Price-to-Book 4.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.55
Resistance 3 (R3) 9.61 9.28 9.36
Resistance 2 (R2) 9.28 8.99 9.26 9.30
Resistance 1 (R1) 8.85 8.81 8.69 8.79 9.23
Pivot Point 8.52 8.52 8.44 8.50 8.52
Support 1 (S1) 8.09 8.23 7.93 8.03 7.59
Support 2 (S2) 7.76 8.05 7.74 7.52
Support 3 (S3) 7.33 7.76 7.46
Support 4 (S4) 7.27